Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripheral Neuropathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    458 result(s) found for: Peripheral Neuropathy. Displaying page 5 of 23.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-000557-35 Sponsor Protocol Number: NW-1029/001/II/2003 Start Date*: 2005-06-09
    Sponsor Name:Newron Pharmaceuticals SpA
    Full Title: A phase II, multi centre, pilot, randomised, ascending dose, double -blind, placebo controlled, dose titration study to determine the safety, maximum tolerated dose and preliminary evidence of effi...
    Medical condition: Neuropathic pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001371-24 Sponsor Protocol Number: 6621 Start Date*: 2019-01-08
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies
    Medical condition: Primary Sjögren's syndrome associated painful sensory neuropathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000281-39 Sponsor Protocol Number: CEMA401A2202 Start Date*: 2018-03-08
    Sponsor Name:Novartis Pharma AG
    Full Title: A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EM...
    Medical condition: Painful Diabetic Neuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (Prematurely Ended) HU (Completed) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) SK (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000009-25 Sponsor Protocol Number: 19PH226 Start Date*: 2021-04-12
    Sponsor Name:CHU SAINT-ETIENNE
    Full Title: Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study
    Medical condition: Anti-MAG neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066137 Anti-MAG neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003453-18 Sponsor Protocol Number: RH-2015-200 Start Date*: 2015-11-25
    Sponsor Name:Rigshospitalet
    Full Title: A Randomized, Single-blinded, Cross-over Study investigating the Non-inferiority of Efficacy and Safety of HyQvia in comparison with Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropa...
    Medical condition: Multifocal Motor Neuropathy (MMN)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10064135 Polyneuropathy chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000407-16 Sponsor Protocol Number: 2197944/202 Start Date*: 2013-07-24
    Sponsor Name:Convergence Pharmaceuticals Ltd
    Full Title: A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic periphe...
    Medical condition: Neuropathic pain associated with diabetic peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2021-006048-29 Sponsor Protocol Number: INjECT Start Date*: 2022-02-21
    Sponsor Name:AOU MATERDOMINI
    Full Title: BotulInum toxin type A for peripheral Neuropathic pain in subjEcts with Carpal Tunnel syndrome: a multicenter, randomized, double-blind, placebo-controlled study
    Medical condition: Peripheral neuropathic pain in subjects with carpal tunnel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10007698 Carpel tunnel syndrome LLT
    20.0 100000004852 10077974 Peripheral neuropathic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004318-14 Sponsor Protocol Number: NEOD001-201 Start Date*: 2016-06-13
    Sponsor Name:Prothena Therapeutics Limited
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction
    Medical condition: Light chain (AL) amyloidosis involves a hematologic disorder caused by clonal plasma cells that produce misfolded immunoglobulin light chains. Overproduction of misfolded light chains results in bo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10036673 Primary amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) GR (Completed) ES (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004746-17 Sponsor Protocol Number: 17HH4283 Start Date*: 2018-03-05
    Sponsor Name:Joint Research Compliance Office, Imperial College London and Imperial College Healthcare NHS Trust
    Full Title: Pain relief with disease modification by Capsaicin 8% patch: a clinical study in Diabetic Peripheral Neuropathy
    Medical condition: Diabetic painful neuropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003727-10 Sponsor Protocol Number: MO40598 Start Date*: 2019-12-16
    Sponsor Name: Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-G...
    Medical condition: Relapsed/refractory diffuse large B-cell lymphoma (DLBL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) SE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003427-36 Sponsor Protocol Number: M10-898 Start Date*: 2012-04-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advance...
    Medical condition: Metastatic or Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10025044 Lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000435-23 Sponsor Protocol Number: ATX01-22-01-CIPN Start Date*: 2022-07-26
    Sponsor Name:AlgoTherapeutix
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15% w/w) in compar...
    Medical condition: chemotherapy-induced peripheral neuropathy (CIPN)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005872-41 Sponsor Protocol Number: QTZ-EC-0004 Start Date*: 2012-04-25
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study
    Medical condition: Patients who have a documented diagnosis of probable or definite Peripheral Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) FI (Completed) AT (Completed) SK (Completed) ES (Completed) BE (Completed) SI (Completed) GB (Completed) DE (Completed) GR (Completed) PT (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000128-16 Sponsor Protocol Number: 2011-003 Start Date*: 2012-07-30
    Sponsor Name:Onyx Therapeutics, Inc.
    Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005855-35 Sponsor Protocol Number: U1111-1270-0943 Start Date*: 2023-01-10
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascu...
    Medical condition: Atherosclerotic cardiovascular disease and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002066-14 Sponsor Protocol Number: 20887 Start Date*: 2020-12-30
    Sponsor Name:Bayer AG
    Full Title: A randomized, placebo-controlled, double-blind, parallel-group, multicenter combined Phase 2a/2b study to assess the efficacy and safety of BAY 1817080 in patients with diabetic neuropathic pain
    Medical condition: Neuropathic pain associated with diabetic peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NO (Completed) CZ (Completed) FI (Completed) SE (Completed) HU (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001392-17 Sponsor Protocol Number: 19636 Start Date*: 2022-01-03
    Sponsor Name:Bayer AG
    Full Title: A randomized, double-blind, cross-over, placebo-controlled, multi-center, Phase 2a study to assess the safety and efficacy of BAY 2395840 in patients with diabetic neuropathic pain.
    Medical condition: Neuropathic pain associated with diabetic peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001356-20 Sponsor Protocol Number: 0602001 Start Date*: 2006-06-05
    Sponsor Name:Reckitt Benckiser (UK) Limited
    Full Title: A preliminary single dose, three-way, double-blind, placebo-controlled crossover study of intravenous buprenorphine/naloxone in the treatment of neuropathic pain of diabetic neuropathy origin.
    Medical condition: Neuropathic pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-000879-26 Sponsor Protocol Number: 311602-Amendment 1 Start Date*: 2008-08-07
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: (REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.
    Medical condition: - Advanced refractory or relapsed ovarian cancer - Patients with metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001427-40 Sponsor Protocol Number: ION-682884-CS13 Start Date*: 2022-06-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Medical condition: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) CY (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 00:42:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA